

Our Ref: 506/2023  
October 2023

## Re: Your request made under the Freedom of Information Act 2000

I have a freedom of information request.

A. We are seeking to understand the funding and delivery of Botox and anti-CGRP monoclonal antibody treatments (Ajoovy, Aimovig, Emgality, Vyepiti, Vydura & Aquipta) for migraine. Could you please answer the following:

- Does the trust commission/fund Botox treatment for migraine (Y/N)? **No**
- Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)? **No**
- Does the trust actively provide Botox/anti-CGRP treatments for migraine as opposed to sending patients to another trust (Y/N)? In case the trust does not provide these treatments, please provide the name of the trust to which you refer migraine patients for these treatments? **No – we do not refer onto other trusts**
- In case the trust actively provides Botox/anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust. **NA**

B. How many patients have been treated with the following drugs in the past 4 months:

- · Atogepant (Aquipta) – any disease - 0
- · Erenumab (Aimovig) - any disease - 0
- · Eptinezumab (Vyepiti) – any disease - 0
- · Fremanezumab (Ajoovy) - any disease - 0
- · Galcanezumab (Emgality) - any disease - 0
- · Rimegepant (Vydura) – any disease - 0
- · Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY – unknown, the pharmacy system does not store data on indications